Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $CCCC
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/19/2024 | $8.00 → $12.00 | Equal Weight → Overweight | Wells Fargo |
11/18/2024 | $4.00 | Equal-Weight | Stephens |
1/29/2024 | $6.00 | Underweight → Neutral | JP Morgan |
12/13/2023 | $2.00 → $12.00 | Hold → Buy | Stifel |
2/24/2023 | $12.00 → $10.00 | Underperform → Neutral | Credit Suisse |
2/24/2023 | $15.00 → $5.00 | Neutral → Underweight | JP Morgan |
11/4/2022 | $22.00 → $15.00 | Overweight → Neutral | JP Morgan |
10/11/2022 | $6.00 | Underweight | Morgan Stanley |
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended
C4 Therapeutics to Participate in Upcoming March Investor Conferences
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences. TD Cowen 45th Annual Healthcare Conference: Management will present on March 3rd at 9:10 am ET in Boston, MA. The live webcast will be available on the Events & Presentations page of the company's website. The archived replay of the webcast will be available for approximately 30 days following the live event. Leerink Partners Global Healthcare Conference: Management will participate in the confer
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma CFT1946 Phase 1 Trial Continues to Progress in BRAF V600X Solid Tumors With Monotherapy Dose Escalation Expected to Complete in 1H 2025; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 CFT8919 Progressing Through Phase 1 Dose Escalation in Greater China; Phase 1 Data Will Inform Future Development Plans Outside of China Cash Runway Expected to Fund Operations Into 2027 WATERTOWN, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (
C4 Therapeutics upgraded by Wells Fargo with a new price target
Wells Fargo upgraded C4 Therapeutics from Equal Weight to Overweight and set a new price target of $12.00 from $8.00 previously
Stephens initiated coverage on C4 Therapeutics with a new price target
Stephens initiated coverage of C4 Therapeutics with a rating of Equal-Weight and set a new price target of $4.00
C4 Therapeutics upgraded by JP Morgan with a new price target
JP Morgan upgraded C4 Therapeutics from Underweight to Neutral and set a new price target of $6.00
President & CEO Hirsch Andrew covered exercise/tax liability with 22,217 shares and was granted 223,500 shares, increasing direct ownership by 91% to 423,145 units (SEC Form 4)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
Chief Legal Officer Siegel Jolie covered exercise/tax liability with 5,049 shares and was granted 56,500 shares, increasing direct ownership by 91% to 107,939 units (SEC Form 4)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
Chief Business Officer Boyle Scott N covered exercise/tax liability with 4,103 shares, was granted 56,500 shares and sold $3,651 worth of shares (1,159 units at $3.15), increasing direct ownership by 91% to 107,805 units (SEC Form 4)
4 - C4 Therapeutics, Inc. (0001662579) (Issuer)
SEC Form S-8 filed by C4 Therapeutics Inc.
S-8 - C4 Therapeutics, Inc. (0001662579) (Filer)
SEC Form 10-K filed by C4 Therapeutics Inc.
10-K - C4 Therapeutics, Inc. (0001662579) (Filer)
C4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels Multiple Myeloma Arm Demonstrated Well-Tolerated Safety Profile; On-Target Neutropenia Was Manageable With Low Rates of Febrile Neutropenia and Infections; No Treatment Emergent Adverse Events Leading to Dose Reduction In Non-Hodgkin's Lymphoma, Cemsidomide Monotherapy Demonstrated a 38 Percent ORR and 19 Percent Complete Metabolic Response (CMR) Rate Across All Subtypes; In Peripheral T-Cell Lymphoma (PTCL), Cemsidomide Achieved a 44 Percent ORR and 25 Perc
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director. "Our commitment to assembling a group of industry experts who offer diverse perspectives to our Board has resulted in bringing on some of the industry's brightest minds
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader
– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies – – CFT7455 Exhibits Differentiated Pharmacokinetics (PK) and Potency Relative to Approved and Investigational IKZF1/3 Degraders – – On-Target Dose Limiting Toxicity Observed; Modeling Suggests Differentiated Activity and PK Profile Provides Pathway to Increase Therapeutic Index with Alternative Dosing Schedule – – Company to Host Conference Call and Webcast Today at 2 pm ET – WATERTOWN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical co
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
- Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – - New Pre-clinical Data from CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted as Oral Presentations – - Conference Call and Webcast Scheduled for April 8, 2022, at 2 PM ET– WATERTOWN, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will pr
Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.
SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)
SEC Form SC 13G filed by C4 Therapeutics Inc.
SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)
Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.
SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)